.)
The PHE-linked measures that are particularly relevant for healthcare providers include enhanced coverage and waived cost-sharing for COVID-19 tests and vaccines across payors, increased Medicare reimbursement for COVID-19-related hospital discharges, and loosened restrictions related to post-acute care facilities.
With respect to Medicaid, FFCRA’s 6.2 percentage point boost to the federal Medicaid match rate remains in effect through the end of the calendar quarter in which the PHE expires, which would now be March 31. The same end date applies to the “maintenance of effort” requirement that prohibits restrictive new eligibility measures, as well as the mandate for states to cover, without cost-sharing, any FDA-authorized COVID‑19 test, treatment or vaccine. Meanwhile, the so-called “continuous coverage” requirement which prohibits state Medicaid agencies from disenrolling any beneficiaries lasts until the end of the
Press release content from Accesswire. The AP news staff was not involved in its creation.
Jaguar Health Enters Non-dilutive Binding Term Sheet for $6.0 Million Sale of Partial Rights to Possible Tropical Disease Priority Review Voucher
January 13, 2021 GMT
This additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic relief of diarrhea and dehydration in cholera patients
REMINDER: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time. Webcast registration and participation link appears below
SAN FRANCISCO, CA / ACCESSWIRE / January 13, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) announced today that the Company has entered a binding agreement of terms (the “Term Sheet”) for $6.0 million for the sale of partial rights to a possible tropical disease priority review voucher (“TDPRV”). Per the terms of the Term Sheet, Streeterville Capital, L
(2)
This additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic relief of diarrhea and dehydration in cholera patients
REMINDER: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time. Webcast registration and participation link appears below
SAN FRANCISCO, CA / ACCESSWIRE / January 13, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ( Jaguar or the Company ) announced today that the Company has entered a binding agreement of terms (the Term Sheet ) for $6.0 million for the sale of partial rights to a possible tropical disease priority review voucher ( TDPRV ). Per the terms of the Term Sheet, Streeterville Capital, LLC (the Investor ), has a right to 18% of the sale of a TDPRV that Jaguar s wholly owned subsidiary, Napo Pharmaceuticals, Inc. (Napo) plans to pursue as incentive for the development of Napo s lechlemer drug product candidate for the indication of the symptomatic relief
(StatePoint) Each year, millions of Americans get sick from “seasonal influenza” (“the flu”). According to the Centers for Disease Control and Prevention (CDC), more than 38 million people got sick